Long-term Prognosis of Patients Undergoing Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Comparison of Cisplatin Lipiodol Suspension and Doxorubicin Hydrochloride Emulsion

Liver Fibrosis and Five Year Survival of Hepatocellular Cancer Cases Undergoing Transcatheter Arterial Chemo Embolization Using Small Doses

“…Camma et al (2008) summarized several randomized controlled trials in Europe, the study suggested that short-term curative effect improved by decreasing doses of chemotherapeutics. Kamada et al (2009) reported that PHC patients treated with low doses and conventional doses of chemotherapeutics, patients, 1, 3, 5, 7 years of survival rate were 81%, 41%, 19% and 13%. Thus, TACE with low doses chemotherapy drugs may have important significance to patients' later chronic liver injury and fibrosis and is beneficial to patients' long-term survival.…”

“…Hong Li 1 *, Yaohong Hu 2 , Na Li 2 , Yan Zhou 1 in liver parenchyma (Chung et al, 1996;Bruix 1997) and cell necrosis was visible (Therasse et al, 2000;Kamada et al, 2001) surrounding the iodized oil deposition areas. So only using super-selective intubation treatment to reduce the liver fibrosis that caused by TACE was not enough, because hepatocarcinoma were not that sensitive to chemotherapeutics, and liver fibrosis was caused by huge doses chemotherapeutics drugs in TACE.…”

Transcatheter Arterial Chemo-Embolization with a Fine-Powder Formulation of Cisplatin for Unresectable Hepatocellular Carcinoma

“…Other investigators have also frequently reported favorable results obtained with TACE using a suspension of CDDP powder in LPD in HCC patients. 16,24 However, the CDDP powder for this therapy was difficult to produce because of the characteristics of the drug formulation. CDDP powder thus had to be custom-made in individual institutions.…”

“…14 Researchers have recently reported that TACE using a suspension of CDDP in LPD may be more effective against unresectable HCC than that using ADM-LPD emulsion. 15,16 Moreover, a fine-powder formulation of CDDP (DDPH, IA-call; Nipponkayaku, Tokyo, Japan) has also been available since 2004 as a therapeutic agent for intra-arterial infusion in Japan.…”

Future perspectives on the treatment of hepatocellular carcinoma with cisplatin

“…However, combined regimens containing CDDP and lipiodol have been reported to yield response rates of 15%-57%, while corresponding rates of 45%-73% have been reported for the treatment combined with embolization using gelatin sponge particles. Thus, the response rates of TACE tend to be higher than other chemotherapies [5,6,20,[40][41][42][43][44][45][46][47][48][49][50] (Table 3). Two relevant randomized controlled studies have been reported.…”